EPITOPE INC/OR/
10-Q, EX-27, 2000-08-08
IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES
Previous: EPITOPE INC/OR/, 10-Q, 2000-08-08
Next: CREDIT SUISSE FIRST BOSTON MORTGAGE SECURITIES CORP, S-3/A, 2000-08-08



<TABLE> <S> <C>

<ARTICLE>                     5
<LEGEND>
This  schedule  contains  summary  financial   information  extracted  from  the
condensed  consolidated financial statements included herein and is qualified in
its entirety by reference to such financial statements.
</LEGEND>
<MULTIPLIER>                                         1

<S>                                                  <C>
<PERIOD-TYPE>                                        9-MOS
<FISCAL-YEAR-END>                                    SEP-30-2000
<PERIOD-START>                                       OCT-01-1999
<PERIOD-END>                                         JUN-30-2000
<CASH>                                                  7,735,883
<SECURITIES>                                            7,828,048
<RECEIVABLES>                                           1,991,424
<ALLOWANCES>                                               50,000
<INVENTORY>                                             1,247,648
<CURRENT-ASSETS>                                       19,346,758
<PP&E>                                                  6,824,502
<DEPRECIATION>                                          5,100,207
<TOTAL-ASSETS>                                         21,596,936
<CURRENT-LIABILITIES>                                   1,856,958
<BONDS>                                                         0
                                           0
                                                     0
<COMMON>                                              127,630,583
<OTHER-SE>                                           (107,890,605)
<TOTAL-LIABILITY-AND-EQUITY>                           21,596,936
<SALES>                                                 8,984,602
<TOTAL-REVENUES>                                        9,101,721
<CGS>                                                   3,483,775
<TOTAL-COSTS>                                          11,726,679
<OTHER-EXPENSES>                                         (595,986)
<LOSS-PROVISION>                                                0
<INTEREST-EXPENSE>                                       (389,569)
<INCOME-PRETAX>                                        (1,639,403)
<INCOME-TAX>                                                    0
<INCOME-CONTINUING>                                             0
<DISCONTINUED>                                                  0
<EXTRAORDINARY>                                                 0
<CHANGES>                                                       0
<NET-INCOME>                                           (1,639,403)
<EPS-BASIC>                                                 (0.11)
<EPS-DILUTED>                                               (0.11)


</TABLE>


© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission